Trial Profile
The EFV Central Nervous System Exposure Sub-study of Encore1: A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals Over 96 Weeks
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Acronyms ENCORE1-CNS
- 17 Jun 2016 New trial record